GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of dual agonist is the most under-discussed thing on this board — 28 comments in the full submission. View in context.
479
c/survodutide·submitted 7 months ago by u/renzo_asante

dual agonist is the most under-discussed thing on this board

Paperbranch of 6 comments

dual agonist is the most under-discussed thing on this board. I have gone back and forth on this for months. Phase 2 in a biopsy-confirmed population is a demanding design: recruitment is slow, the population is specific, and the results do not generalise to people who have not been characterised that way. It is a…

Read the full submission and all 28 comments →

This branch

6 comments, started 7 months ago
u/border_paperwork18 points·7 months ago

independent testing on this compound is very thin

replysharereportpermalink
u/thermal_mass_tom6 points·7 months ago

not approved anywhere, and the boards forget that constantly

replysharereportpermalink
u/nadia_bakker4 points·7 months ago

Is that a weight number from a different programme?

replysharereportpermalink
u/kasper_cabrera3 points·7 months ago·edited

Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.

replysharereportpermalink
u/andres_dahlberg2 points·7 months ago

Agreed. The hepatic programme is the point of this compound and the weight discussion is a side effect of the side effect.

replysharereportpermalink
u/cato_batista1 point·7 months ago

Which phase and which arm are you quoting?

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →